CN119731179A - Ikzf2降解剂及其用途 - Google Patents

Ikzf2降解剂及其用途 Download PDF

Info

Publication number
CN119731179A
CN119731179A CN202380041783.5A CN202380041783A CN119731179A CN 119731179 A CN119731179 A CN 119731179A CN 202380041783 A CN202380041783 A CN 202380041783A CN 119731179 A CN119731179 A CN 119731179A
Authority
CN
China
Prior art keywords
carbocyclyl
alkyl
heterocyclyl
compound
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380041783.5A
Other languages
English (en)
Chinese (zh)
Inventor
陈志翔
R·雷吉
张旭庆
白龙川
P·基尔希霍夫
王少萌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weng Kopia Treatment Co And Sk Life Science Laboratory
University of Michigan-Ann Arbor
Original Assignee
Weng Kopia Treatment Co And Sk Life Science Laboratory
University of Michigan-Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Weng Kopia Treatment Co And Sk Life Science Laboratory, University of Michigan-Ann Arbor filed Critical Weng Kopia Treatment Co And Sk Life Science Laboratory
Publication of CN119731179A publication Critical patent/CN119731179A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380041783.5A 2022-03-25 2023-03-24 Ikzf2降解剂及其用途 Pending CN119731179A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263323792P 2022-03-25 2022-03-25
US63/323,792 2022-03-25
US202363446105P 2023-02-16 2023-02-16
US63/446,105 2023-02-16
PCT/US2023/016177 WO2023183540A1 (en) 2022-03-25 2023-03-24 Ikzf2 degraders and uses thereof

Publications (1)

Publication Number Publication Date
CN119731179A true CN119731179A (zh) 2025-03-28

Family

ID=86185384

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380041783.5A Pending CN119731179A (zh) 2022-03-25 2023-03-24 Ikzf2降解剂及其用途

Country Status (7)

Country Link
US (1) US20250215012A1 (enExample)
EP (1) EP4499649A1 (enExample)
JP (1) JP2025512805A (enExample)
KR (1) KR20250026153A (enExample)
CN (1) CN119731179A (enExample)
TW (1) TW202341988A (enExample)
WO (1) WO2023183540A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
EP4471033A4 (en) * 2022-01-29 2026-03-25 Gan & Lee Pharmaceuticals Co Ltd CEREBLON UBIQUITIN LIGASE E3 INHIBITOR
CN117065022A (zh) * 2022-05-17 2023-11-17 海创药业股份有限公司 一种治疗三阴乳腺癌的药物
WO2025261456A1 (zh) * 2024-06-19 2025-12-26 甘李药业股份有限公司 一种雌激素受体蛋白降解靶向嵌合体化合物及其应用
WO2026035999A1 (en) 2024-08-09 2026-02-12 Triana Biomedicines, Inc. Anaplastic lymphoma kinase (alk) degraders and uses thereof
WO2026139085A1 (zh) * 2024-12-27 2026-07-02 甘李药业股份有限公司 酪蛋白激酶1α(CK1α)分子胶降解剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CA3123519A1 (en) * 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2021087093A1 (en) * 2019-10-30 2021-05-06 Dana-Farber Cancer Institute, Inc. Small molecule degraders of helios and methods of use
EP4168007A1 (en) * 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en) * 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof

Also Published As

Publication number Publication date
KR20250026153A (ko) 2025-02-25
US20250215012A1 (en) 2025-07-03
JP2025512805A (ja) 2025-04-22
EP4499649A1 (en) 2025-02-05
TW202341988A (zh) 2023-11-01
WO2023183540A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
AU2008292390B2 (en) Polycyclic compound
EP2686325B1 (en) Morpholine-spirocyclic piperidine amides as modulators of ion channels
EP4499649A1 (en) Ikzf2 degraders and uses thereof
EP3154976B1 (en) Purine inhibitors of human phosphatidylinositol 3-kinase delta
WO2020103896A1 (en) Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof
BR112020003373B1 (pt) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona, usos dos mesmos e composição farmacêutica
US20250195484A1 (en) Cereblon ligands and uses thereof
KR102731924B1 (ko) 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물
WO2022165513A1 (en) Cdk2 inhibitors and methods of using the same
EA018670B1 (ru) Производные пиразоло[3,4-в]пиридина в качестве ингибиторов фосфодиэстеразы
CN119585252A (zh) 作为ikzf2降解剂的含二环杂芳基的化合物
CN116113698A (zh) Trpml调节剂
EP4457230A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
WO2024192064A1 (en) Compounds and compositions as smarca2/4 degraders and uses thereof
CN120787229A (zh) 取代的3,4-二氢异喹啉-1(2h)-酮衍生物及相关用途
US20240034731A1 (en) Aza-quinazoline compounds and methods of use
WO2024064316A1 (en) Compounds and compositions as smarca2/4 inhibitors and uses thereof
WO2023201012A1 (en) Ikzf2 degraders and uses thereof
EP4493545A2 (en) Fused pyrazole amide analogs as glucosylceramide synthase inhibitors
HK40123006A (en) Ikzf2 degraders and uses thereof
HK40123004A (en) Bicyclic heteroaryl-containing compounds as ikzf2 degraders
WO2025106472A1 (en) Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025106480A1 (en) Compounds and compositions as smarca2/4 degraders and uses thereof
EA048618B1 (ru) Макроциклические ингибиторы rip2-киназы

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40123006

Country of ref document: HK